Correction: External control arms for rare diseases: building a body of supporting evidence
Artak Khachatryan, Stephanie H Read, Terri Madison
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsGenomics and Rare Diseases
Correction to: Journal of Pharmacokinetics and Pharmacodynamics (2023) 50:501-506
10.1007/s10928-023-09858-8
In this article, under the section heading ‘Blinatumomab case study’ third paragraph should have been read as below:
To provide further support of the efficacy of blinatumomab relative to existing therapies, findings from a model-based meta-analysis study (‘synthetic control arm’) were presented. Data from 21 clinical studies published between 1995 and 2012 were manually extracted and used to develop mixed-effects meta-analysis models. In hindsight, this process can be substantially streamlined when using databases such as Certara’s Clinical Outcomes Database Explorer (CODEx) Clinical Trial Outcomes Databases [1]. The blinatumomab models were subsequently used to simulate the effect of blinatumomab relative to existing salvage therapies. The estimated CR rate of existing therapies was 13% (95% CI 4%-34%) and the odds ratio of CR for blinatumomab compared to existing therapies was 3.50 (95% CI: 1.63–8.40) [2].
The reference list from the paper itself. Each links out to its DOI / PubMed record.